7 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 4 Phase 3, 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Ozempic®: new trials by email Literature Review of Ozempic® trials Research Report on Ozempic®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes F027, Ozempic® - Type 2 Diabetes (T2DM) | Phase 3 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 496 | 2025-08-01 | 2025-07-01 |
| Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity Ozempic® - Obesity and Overweight, Obese Adolescents | Recruiting | John Bauer | 50 | 2025-06-12 | 2026-07-21 | |
| Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. Ozempic®, HDG1901 - Type 2 Diabetes | Phase 1 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 68 | 2024-09-22 | 2025-08-01 |
| A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment Semaglutide - Diabetes Mellitus, Type 2 | Completed | Novo Nordisk A/S | 304 | 2024-06-26 | 2026-02-11 | |
| Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes Semaglutide Injection, Semaglutide Injection(Ozempic®), Metformin - Type 2 Diabetes Mellitus | Phase 3 | Unknown | Chengdu Brilliant Pharmaceutical Co., Ltd. | 478 | 2024-04-01 | 2024-04-01 |
| Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus semaglutide injection (HD1916), Ozempic® - Type 2 Diabetes Mellitus | Phase 3 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 506 | 2024-02-23 | 2025-07-11 |
| Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes Ozempic®, HDG1901 - Type 2 Diabetes | Phase 3 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 494 | 2023-09-20 | 2025-07-28 |
| A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL - Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 145 | 2021-08-04 | 2023-11-15 |
| Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data Ozempic®, Active Comparator, Rybelsus® - Diabetes Mellitus, Type 2 | Completed | Novo Nordisk A/S | 194928 | 2021-01-26 | 2026-06-11 | |
| A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together NNC0148-0287sema, Semaglutide, NNC0148-0287 - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Novo Nordisk A/S | 30 | 2019-01-17 | 2024-11-12 |
Diabetes Mellitus, Type 2 (8) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1) · Overweight (1) · Weight Loss (1)
Novo Nordisk A/S (3) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Chengdu Brilliant Pharmaceutical Co., Ltd. (1) · John Bauer (1) · Merck Sharp & Dohme LLC (1) · Shandong New Time Pharmaceutical Co., LTD (1)
China (3) · United States (2) · Argentina (1) · Australia (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Mexico (1) · New Zealand (1) · Poland (1) · Russia (1)
Aurelia Radulescu, MD (1) · Dalong Zhu, PhD (1) · John Bauer, PhD (1) · Margaret Murphy, RD PhD (1)
2017 (1)